Schistosomiasis is an acute and chronic disease caused by the parasitic worm Schistosoma genus. Schistosomiasis is also known as Bilharzia, Blood fluke, and Katayama fever. The disease is spread through waterborne transmission. Schistosoma parasites are found in rivers, lakes, water parks, ponds, swimming pools, municipal water, and streams. Schistosomamansoni, S. haematobium, S. japonicum, S. mekongi and S. intercalatum are common parasites of schistosomiasis. Infection can spread through direct contact with the infected animal and person. Schistosomiasis transmission had been reported from 78 countries, in 2015.
Schistosomiasis symptoms occur when the body reacts to the worms' eggs. Diarrhea, abdominal cramps, blood in the stool, vomiting, liver enlargement, blood in urine, kidney damage, fever, rash, body aches,and weakness are signs and symptoms of the disease. Other chronic symptoms include vaginal bleeding, genital lesions, and nodules in the vulva, seminal vesicles, paralysis, seizures, Healthcare professionals recommend repeated examination to confirm the schistosomiasis parasite in the stool and urine. Blood test and polymerase chain reaction (PCR) tests also help to diagnose schistosomiasis. If no eggs are found in urine or feces other tests such as colonoscopy, endoscopy, ultrasound, echocardiograms, MRI, and liver biopsy can be recommended for better diagnosis. If schistosomiasis is left untreated, it can lead to complications related to cardiopulmonary, central nervous system, gastrointestinal, liver, spleen, bacterial infections, urinary obstruction, and even death.
Currently, praziquantel drug is used to treat schistosomiasis and is more effective on adult worms; however, no effective medication is available in the market for eggs or immature worms. Corticosteroids are also used to treat the disease. Oxamniquine, artemisinins, metrifonate, and trioxolanes are other drugs to treat schistosomiasis, however these drugs are less effective, while a few others are under development. Surgical alternativescan include the removal of tumors, shunt surgeries, and granuloma removal. Increasing scarcity of clean water supplies in Africa, Asia, and Latin America increase the proliferation of the disease, impelling the schistosomiasis drugs market. Lack of the disease awareness is the key restraint of the market.
The schistosomiasis drugs market can be segmented based on drug class, distribution channel, end-user, and region. In terms of drug class, the market can be categorized into anthelmintic or anti-worm and others. Based on distribution channel the market is categorized into hospital pharmacy, retail pharmacy, and online sales. The hospital pharmacy segment held the largest share in the schistosomiasis drugs market. The segment is projected to expand at a significant CAGR during the forecast period. The online sales segment is expected to gain market share during the forecast period, due to the growing use of mobile-based applications for ordering medicines.
In terms of region, the global schistosomiasis drugs market can be segmented into Middle East & Africa, Latin America, Asia Pacific, Europe, and North America. Middle East & Africa is the largest market for schistosomiasis drugs, followed by Latin America, Asia, Europe, and North America. In terms of revenue, South Africa is a major contributor to the schistosomiasis drugs market in Middle East & Africa. The market in Latin America is expanding rapidly due to an increase in the patient population, especially in Brazil. However, Asia Pacific and Europe are projected to grow in the near future. Emerging economies such as China and Japan are projected to contribute to the regional growth due to better health care infrastructure, economic growth, improving insurance payers, expanding and developing private health care sector, and increasing awareness.
Key players operating in the global schistosomiasis drugs market are Bayer AG, Merck KGaA, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceuticals Industries Ltd., and Mylan N.V.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.